Janux Therapeutics Stock Current Valuation

JANX Stock  USD 32.01  0.59  1.81%   
Valuation analysis of Janux Therapeutics helps investors to measure Janux Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Enterprise Value is likely to rise to about 2.6 B in 2025, whereas Enterprise Value Over EBITDA is likely to drop (26.24) in 2025. Fundamental drivers impacting Janux Therapeutics' valuation include:
Price Book
2.865
Enterprise Value
1.2 B
Enterprise Value Ebitda
(33.80)
Price Sales
143.8299
Enterprise Value Revenue
95.4225
Undervalued
Today
32.01
32.032.0146.546.4990.290.2331.931.9332.132.08100%
Please note that Janux Therapeutics' price fluctuation is not too volatile at this time. Calculation of the real value of Janux Therapeutics is based on 3 months time horizon. Increasing Janux Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Janux Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Janux Stock. However, Janux Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Historical Market  32.01 Real  46.49 Target  90.23 Hype  31.93 Naive  32.08
The intrinsic value of Janux Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Janux Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
46.49
Real Value
54.26
Upside
Estimating the potential upside or downside of Janux Therapeutics helps investors to forecast how Janux stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Janux Therapeutics more accurately as focusing exclusively on Janux Therapeutics' fundamentals will not take into account other important factors:
Earnings
Estimates (0)
LowProjectedHigh
-0.73-0.47-0.33
Details
Hype
Prediction
LowEstimatedHigh
24.1631.9339.70
Details
Naive
Forecast
LowNext ValueHigh
24.3232.0839.85
Details
14 Analysts
Consensus
LowTarget PriceHigh
82.1190.23100.16
Details

Janux Therapeutics Company Current Valuation Analysis

Janux Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Enterprise Value

 = 

Market Cap + Debt

-

Cash

More About Current Valuation | All Equity Analysis

Current Janux Therapeutics Current Valuation

    
  1.25 B  
Most of Janux Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Janux Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Janux Current Valuation Driver Correlations

Understanding the fundamental principles of building solid financial models for Janux Therapeutics is extremely important. It helps to project a fair market value of Janux Stock properly, considering its historical fundamentals such as Current Valuation. Since Janux Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Janux Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Janux Therapeutics' interrelated accounts and indicators.
1.00.97-0.48-0.891.00.81.0-0.411.01.01.0-0.811.00.870.530.69
1.00.97-0.49-0.881.00.771.0-0.411.01.01.0-0.81.00.850.540.68
0.970.97-0.44-0.90.970.760.97-0.590.970.960.97-0.820.960.90.550.72
-0.48-0.49-0.440.1-0.47-0.27-0.49-0.19-0.5-0.44-0.50.6-0.44-0.13-0.930.12
-0.89-0.88-0.90.1-0.89-0.86-0.880.62-0.88-0.91-0.880.7-0.91-0.98-0.23-0.81
1.01.00.97-0.47-0.890.81.0-0.431.01.01.0-0.831.00.860.510.7
0.80.770.76-0.27-0.860.80.77-0.430.780.810.78-0.80.810.870.310.72
1.01.00.97-0.49-0.881.00.77-0.411.01.01.0-0.81.00.850.540.68
-0.41-0.41-0.59-0.190.62-0.43-0.43-0.41-0.41-0.42-0.410.4-0.42-0.69-0.01-0.8
1.01.00.97-0.5-0.881.00.781.0-0.411.01.0-0.821.00.850.550.68
1.01.00.96-0.44-0.911.00.811.0-0.421.01.0-0.791.00.880.490.72
1.01.00.97-0.5-0.881.00.781.0-0.411.01.0-0.821.00.850.550.68
-0.81-0.8-0.820.60.7-0.83-0.8-0.80.4-0.82-0.79-0.82-0.79-0.68-0.53-0.51
1.01.00.96-0.44-0.911.00.811.0-0.421.01.01.0-0.790.880.490.72
0.870.850.9-0.13-0.980.860.870.85-0.690.850.880.85-0.680.880.30.85
0.530.540.55-0.93-0.230.510.310.54-0.010.550.490.55-0.530.490.3-0.01
0.690.680.720.12-0.810.70.720.68-0.80.680.720.68-0.510.720.85-0.01
Click cells to compare fundamentals

Janux Current Valuation Historical Pattern

Today, most investors in Janux Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Janux Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Janux Therapeutics current valuation as a starting point in their analysis.
   Janux Therapeutics Current Valuation   
       Timeline  
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Competition

In accordance with the recently published financial statements, Janux Therapeutics has a Current Valuation of 1.25 B. This is 91.33% lower than that of the Biotechnology sector and 73.2% lower than that of the Health Care industry. The current valuation for all United States stocks is 92.51% higher than that of the company.

Janux Current Valuation Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Janux Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Janux Therapeutics could also be used in its relative valuation, which is a method of valuing Janux Therapeutics by comparing valuation metrics of similar companies.
Janux Therapeutics is currently under evaluation in current valuation category among its peers.

Janux Therapeutics Current Valuation Drivers

We derive many important indicators used in calculating different scores of Janux Therapeutics from analyzing Janux Therapeutics' financial statements. These drivers represent accounts that assess Janux Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Janux Therapeutics' important valuation drivers and their relationship over time.
202020212022202320242025 (projected)
Enterprise Value1.0B778.3M520.0M477.6M2.5B2.6B

Janux Therapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Janux Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Janux Therapeutics' managers, analysts, and investors.
Environmental
Governance
Social

Janux Fundamentals

Return On Equity-0.12
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-140%-120%-100%-80%-60%-40%-20%
Return On Asset-0.0993
Operating Margin(81.64) %
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-10%-5%0%5%
Current Valuation1.25 B
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-50%0%50%100%150%
Shares Outstanding58.63 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%5%10%15%20%
Shares Owned By Insiders7.22 %
Shares Owned By Institutions92.78 %
Number Of Shares Shorted9.09 M
Price To Book2.87 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-100%-80%-60%-40%-20%
Price To Sales143.83 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-80%-60%-40%-20%0%20%
Revenue8.08 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Gross Profit(46.77 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-150,000%-100,000%-50,000%0%
EBITDA(71.02 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31500%1,000%1,500%
Net Income(58.29 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31200%400%600%800%1,000%1,200%
Cash And Equivalents338.76 M
Cash Per Share8.15 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-3120,000%40,000%60,000%80,000%100,000%120,000%
Total Debt24.54 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-100%0%100%200%300%400%500%600%
Debt To Equity0.07 %
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-120%-100%-80%-60%-40%-20%
Current Ratio21.08 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-3110,000%20,000%30,000%40,000%
Book Value Per Share12.54 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-10,000%-8,000%-6,000%-4,000%-2,000%0%
Cash Flow From Operations(50.58 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31200%400%600%800%1,000%1,200%
Short Ratio9.48 X
Earnings Per Share(1.17) X
Price To Earnings To Growth(0.98) X
Target Price89.08
Number Of Employees76
Beta3.16
Market Capitalization1.88 B
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-50%0%50%100%150%
Total Asset380.41 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-3110,000%20,000%30,000%40,000%50,000%60,000%
Retained Earnings(168.76 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31500%1,000%1,500%2,000%
Working Capital336.21 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Net Asset380.41 M

About Janux Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Janux Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Janux Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Janux Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Janux Stock Analysis

When running Janux Therapeutics' price analysis, check to measure Janux Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Janux Therapeutics is operating at the current time. Most of Janux Therapeutics' value examination focuses on studying past and present price action to predict the probability of Janux Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Janux Therapeutics' price. Additionally, you may evaluate how the addition of Janux Therapeutics to your portfolios can decrease your overall portfolio volatility.